Posted on 30/07/2009 in Pharmaceutical Company Product News Wyeth has published positive data from a phase III clinical trial into an investigational compound that is designed to tackle menopausal symptoms.
Published in the journal Fertility and Sterility, the study showed that compound bazedoxifene/conjugated oestrogens significantly reduced the severity and frequency of hot flushes and also improved measures of vaginal atrophy in comparison to a placebo.
The Selective oestrogens Menopause and Response to Therapy (Smart-1) clinical trial aimed to investigate the hypothesis that, when combined with conjugated oestrogens, bazedoxifene could remove the need for progestin in menopausal women with intact uteruses.
Smart-1 was a multinational, multi-centre, double-blind, two-year, randomised study that was both placebo and active-controlled. It involved a total of 3,397 healthy post-menopausal female participants between the ages of 40 and 75.
Earlier this month at the annual meeting of its stockholders, Wyeth announced that the group "overwhelmingly" approved the adoption of the company's merger agreement with Pfizer.Other news stories from 30/07/2009
Read more in the Zenopa News Archive
How this news is generated
|
